(EUZ) Eckert & Ziegler Strahlen - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: XETRA (Germany) | Market Cap: 940m EUR | Total Return: -26.7% in 12m
Avg Turnover: 1.79M
EPS Trend: 36.5%
Rev. Trend: 97.6%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Eckert & Ziegler SE is a Berlin-based provider of isotope technology components, operating through its Medical and Isotope Products segments. The company specializes in the development and manufacturing of radioactive components for medical, scientific, and industrial applications, including prostate cancer seeds, eye applicators, and various radiopharmaceuticals. Its portfolio extends to laboratory equipment, radiation sources for medical imaging, and calibration services for industrial instrumentation.
The company operates within the specialized radiopharmaceutical sector, which requires high capital expenditure and strict regulatory compliance due to the handling of nuclear materials. Unlike traditional pharmaceutical firms, isotope producers rely on complex supply chains involving nuclear reactors or cyclotrons to source raw isotopes before processing them into medical-grade products. This business model benefits from high barriers to entry and a growing demand for targeted radionuclide therapies in oncology.
Investors can find deeper insights into the companys financial health and valuation metrics on ValueRay.
Following a corporate restructuring in March 2024, the firm transitioned from a German Aktiengesellschaft (AG) to a European Company (SE). This change reflects its international footprint across Europe, North America, and Asia, where it serves a diverse client base ranging from hospitals to oil well logging operators.
- Rising global demand for radiopharmaceuticals drives long term medical segment revenue growth
- Expansion of isotope production capacity increases margins through economies of scale
- Regulatory approval timelines for new radioactive implants impact short term market valuation
- Strategic shift toward higher margin therapeutic services offsets industrial isotope price volatility
- Geopolitical stability ensures reliable supply chain for raw isotope material procurement
| Net Income: 49.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -4.80 > 1.0 |
| NWC/Revenue: 57.01% < 20% (prev 54.57%; Δ 2.44% < -1%) |
| CFO/TA 0.12 > 3% & CFO 59.1m > Net Income 49.4m |
| Net Debt (-49.3m) to EBITDA (95.3m): -0.52 < 3 |
| Current Ratio: 3.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.8m) vs 12m ago 0.12% < -2% |
| Gross Margin: 47.10% > 18% (prev 0.48%; Δ 4.66k% > 0.5%) |
| Asset Turnover: 68.25% > 50% (prev 65.64%; Δ 2.62% > 0%) |
| Interest Coverage Ratio: 17.15 > 6 (EBITDA TTM 95.3m / Interest Expense TTM 4.52m) |
| A: 0.38 (Total Current Assets 255.4m - Total Current Liabilities 74.9m) / Total Assets 476.5m |
| B: 0.37 (Retained Earnings 176.7m / Total Assets 476.5m) |
| C: 0.17 (EBIT TTM 77.5m / Avg Total Assets 464.1m) |
| D: 1.17 (Book Value of Equity 242.7m / Total Liabilities 206.9m) |
| Altman-Z'' = 6.05 = AAA |
| DSRI: 1.17 (Receivables 75.5m/60.4m, Revenue 316.8m/296.4m) |
| GMI: 1.02 (GM 47.10% / 48.05%) |
| AQI: 0.95 (AQ_t 0.17 / AQ_t-1 0.18) |
| SGI: 1.07 (Revenue 316.8m / 296.4m) |
| TATA: -0.02 (NI 49.4m - CFO 59.1m) / TA 476.5m) |
| Beneish M = -2.87 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at EUR 15.33 with a total of 167,279 shares traded.
Over the past week, the price has changed by +3.65%,
over one month by +1.79%,
over three months by +1.05% and
over the past year by -26.67%.
Eckert & Ziegler Strahlen has no consensus analysts rating.
P/E Trailing = 19.0127
P/E Forward = 18.2815
P/S = 2.9677
P/B = 3.5371
P/EG = 0.9141
Revenue TTM = 316.8m EUR
EBIT TTM = 77.5m EUR
EBITDA TTM = 95.3m EUR
Long Term Debt = 5.62m EUR (from longTermDebt, last quarter)
Short Term Debt = 9.68m EUR (from shortTermDebt, last quarter)
Debt = 74.6m EUR (from shortLongTermDebtTotal, last quarter) + Leases 31.3m
Net Debt = -49.3m EUR (calculated: Debt 74.6m - CCE 123.9m)
Enterprise Value = 890.6m EUR (939.9m + Debt 74.6m - CCE 123.9m)
Interest Coverage Ratio = 17.15 (Ebit TTM 77.5m / Interest Expense TTM 4.52m)
EV/FCF = 27.55x (Enterprise Value 890.6m / FCF TTM 32.3m)
FCF Yield = 3.63% (FCF TTM 32.3m / Enterprise Value 890.6m)
FCF Margin = 10.21% (FCF TTM 32.3m / Revenue TTM 316.8m)
Net Margin = 15.61% (Net Income TTM 49.4m / Revenue TTM 316.8m)
Gross Margin = 47.10% ((Revenue TTM 316.8m - Cost of Revenue TTM 167.6m) / Revenue TTM)
Gross Margin QoQ = 49.37% (prev 45.09%)
Tobins Q-Ratio = 1.87 (Enterprise Value 890.6m / Total Assets 476.5m)
Interest Expense / Debt = 6.06% (Interest Expense 4.52m / Debt 74.6m)
Taxrate = 33.24% (5.20m / 15.6m)
NOPAT = 51.7m (EBIT 77.5m * (1 - 33.24%))
Current Ratio = 3.41 (Total Current Assets 255.4m / Total Current Liabilities 74.9m)
Debt / Equity = 0.28 (Debt 74.6m / totalStockholderEquity, last quarter 268.4m)
Debt / EBITDA = -0.52 (Net Debt -49.3m / EBITDA 95.3m)
Debt / FCF = -1.52 (Net Debt -49.3m / FCF TTM 32.3m)
Total Stockholder Equity = 244.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.65% (Net Income 49.4m / Total Assets 476.5m)
RoE = 20.26% (Net Income TTM 49.4m / Total Stockholder Equity 244.1m)
RoCE = 31.04% (EBIT 77.5m / Capital Employed (Equity 244.1m + L.T.Debt 5.62m))
RoIC = 12.58% (NOPAT 51.7m / Invested Capital 411.4m)
WACC = 7.83% (E(939.9m)/V(1.01b) * Re(8.13%) + D(74.6m)/V(1.01b) * Rd(6.06%) * (1-Tc(0.33)))
Discount Rate = 8.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 79.57 | Cagr: 0.24%
[DCF] Terminal Value 73.10% ; FCFF base≈40.3m ; Y1≈35.4m ; Y5≈28.6m
[DCF] Fair Price = 8.12 (EV 458.5m - Net Debt -49.3m = Equity 507.8m / Shares 62.6m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 36.51 | EPS CAGR: 5.82% | SUE: N/A | # QB: 0
Revenue Correlation: 97.60 | Revenue CAGR: 12.42% | SUE: 0.02 | # QB: 0
EPS current Year (2026-12-31): EPS=0.83 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+4.5% | GrowthRev=+3.1%
EPS next Year (2027-12-31): EPS=0.90 | Chg30d=N/A | Revisions=-20% | GrowthEPS=+8.3% | GrowthRev=+7.1%
[Analyst] Revisions Ratio: -20%